What We're Reading: Page 323
Industry reads hand-picked by our editors
Nov 02, 2016
-
The New York Times
Glaxo's fallout in China
-
Xconomy
On front lines of price dispute, eye doctors wary of new drug data
-
Buzzfeed News
Here's the fine print on Mark Zuckerberg's plan to cure disease
-
Bloomberg
Investors are hooked on flipping pharmaceuticals
Nov 01, 2016
Oct 31, 2016
-
Boston Business Journal
McKesson stock plunges 25% on drug price scrutiny
-
The Wall Street Journal
Backlash against drug prices hits manufacturers and middlemen
-
The New York Times
Doubts about the promised bounty of genetically modified crops
-
Supply Chain Dive
Supply chain management is a priority for GSK as Brexit looms
Oct 28, 2016
Oct 27, 2016
Oct 26, 2016
Oct 25, 2016
-
The Irish Times
Pfizer cuts price of Enbrel to match rival ‘biosimilar’ drug
-
Medical Marketing & Media
New science drives biopharma interest in neurological conditions
-
TheStreet
Global Blood, FDA reach agreement on pivotal trial design for sickle cell disease drug
-
Chicago Tribune
Chicago may license pharma reps as part of battle against opioid abuse
Previous
